Literature DB >> 35230187

CT-based Radiogenomic Analysis of Clinical Stage I Lung Adenocarcinoma with Histopathologic Features and Oncologic Outcomes.

Rocio Perez-Johnston1, Jose A Araujo-Filho1, James G Connolly1, Raul Caso1, Karissa Whiting1, Kay See Tan1, Jian Zhou1, Peter Gibbs1, Natasha Rekhtman1, Michelle S Ginsberg1, David R Jones1.   

Abstract

Background A preoperative predictive model is needed that can be used to identify patients with lung adenocarcinoma (LUAD) who have a higher risk of recurrence or metastasis. Purpose To investigate associations between CT-based radiomic consensus clustering of stage I LUAD and clinical-pathologic features, genomic data, and patient outcomes. Materials and Methods Patients who underwent complete surgical resection for LUAD from April 2014 to December 2017 with preoperative CT and next-generation sequencing data were retrospectively identified. Comprehensive radiomic analysis was performed on preoperative CT images; tumors were classified as solid, ground glass, or mixed. Patients were clustered into groups based on their radiomics features using consensus clustering, and clusters were compared with tumor genomic alterations, histopathologic features, and recurrence-specific survival (Kruskal-Wallis test for continuous data, χ2 or Fisher exact test for categorical data, and log-rank test for recurrence-specific survival). Cluster analysis was performed on the entire cohort and on the solid, ground-glass, and mixed lesion subgroups. Results In total, 219 patients were included in the study (median age, 68 years; interquartile range, 63-74 years; 150 [68%] women). Four radiomic clusters were identified. Cluster 1 was associated with lepidic, acinar, and papillary subtypes (76 of 90 [84%]); clusters 2 (13 of 50 [26%]) and 4 (13 of 45 [29%]) were associated with solid and micropapillary subtypes (P < .001). The EGFR alterations were highest in cluster 1 (38 of 90 [42%], P = .004). Clusters 2, 3, and 4 were associated with lymphovascular invasion (19 of 50 [38%], 14 of 34 [41%], and 28 of 45 [62%], respectively; P < .001) and tumor spread through air spaces (32 of 50 [64%], 21 of 34 [62%], and 31 of 45 [69%], respectively; P < .001). STK11 alterations (14 of 45 [31%]; P = .006), phosphoinositide 3-kinase pathway alterations (22 of 45 [49%], P < .001), and risk of recurrence (log-rank P < .001) were highest in cluster 4. Conclusion CT-based radiomic consensus clustering enabled identification of associations between radiomic features and clinicalpathologic and genomic features and outcomes in patients with clinical stage I lung adenocarcinoma. © RSNA, 2022 Online supplemental material is available for this article. See also the editorial by Nishino in this issue.

Entities:  

Mesh:

Year:  2022        PMID: 35230187      PMCID: PMC9131171          DOI: 10.1148/radiol.211582

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   29.146


  35 in total

1.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

Authors:  Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke
Journal:  Ann Intern Med       Date:  2007-10-16       Impact factor: 25.391

2.  Prediction of micropapillary and solid pattern in lung adenocarcinoma using radiomic values extracted from near-pure histopathological subtypes.

Authors:  Li-Wei Chen; Shun-Mao Yang; Hao-Jen Wang; Yi-Chang Chen; Mong-Wei Lin; Min-Shu Hsieh; Hsiang-Lin Song; Huan-Jang Ko; Chung-Ming Chen; Yeun-Chung Chang
Journal:  Eur Radiol       Date:  2021-01-03       Impact factor: 5.315

3.  Application of Radiomics in Predicting the Malignancy of Pulmonary Nodules in Different Sizes.

Authors:  Yan Xu; Lin Lu; Lin-Ning E; Wei Lian; Hao Yang; Lawrence H Schwartz; Zheng-Han Yang; Binsheng Zhao
Journal:  AJR Am J Roentgenol       Date:  2019-09-26       Impact factor: 3.959

4.  Multiple primary lung cancers.

Authors:  N Martini; M R Melamed
Journal:  J Thorac Cardiovasc Surg       Date:  1975-10       Impact factor: 5.209

5.  Analysis of Tumor Genomic Pathway Alterations Using Broad-Panel Next-Generation Sequencing in Surgically Resected Lung Adenocarcinoma.

Authors:  Jian Zhou; Francisco Sanchez-Vega; Raul Caso; Kay See Tan; Whitney S Brandt; Gregory D Jones; Shi Yan; Prasad S Adusumilli; Matthew Bott; James Huang; James M Isbell; Smita Sihag; Daniela Molena; Valerie W Rusch; Walid K Chatila; Natasha Rekhtman; Fan Yang; Marc Ladanyi; David B Solit; Michael F Berger; Nikolaus Schultz; David R Jones
Journal:  Clin Cancer Res       Date:  2019-08-27       Impact factor: 12.531

Review 6.  International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.

Authors:  William D Travis; Elisabeth Brambilla; Masayuki Noguchi; Andrew G Nicholson; Kim R Geisinger; Yasushi Yatabe; David G Beer; Charles A Powell; Gregory J Riely; Paul E Van Schil; Kavita Garg; John H M Austin; Hisao Asamura; Valerie W Rusch; Fred R Hirsch; Giorgio Scagliotti; Tetsuya Mitsudomi; Rudolf M Huber; Yuichi Ishikawa; James Jett; Montserrat Sanchez-Cespedes; Jean-Paul Sculier; Takashi Takahashi; Masahiro Tsuboi; Johan Vansteenkiste; Ignacio Wistuba; Pan-Chyr Yang; Denise Aberle; Christian Brambilla; Douglas Flieder; Wilbur Franklin; Adi Gazdar; Michael Gould; Philip Hasleton; Douglas Henderson; Bruce Johnson; David Johnson; Keith Kerr; Keiko Kuriyama; Jin Soo Lee; Vincent A Miller; Iver Petersen; Victor Roggli; Rafael Rosell; Nagahiro Saijo; Erik Thunnissen; Ming Tsao; David Yankelewitz
Journal:  J Thorac Oncol       Date:  2011-02       Impact factor: 15.609

7.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

Review 8.  mTORC1 status dictates tumor response to targeted therapeutics.

Authors:  Ilana Kelsey; Brendan D Manning
Journal:  Sci Signal       Date:  2013-09-24       Impact factor: 8.192

9.  Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.

Authors:  Hira Rizvi; Francisco Sanchez-Vega; Konnor La; Walid Chatila; Philip Jonsson; Darragh Halpenny; Andrew Plodkowski; Niamh Long; Jennifer L Sauter; Natasha Rekhtman; Travis Hollmann; Kurt A Schalper; Justin F Gainor; Ronglai Shen; Ai Ni; Kathryn C Arbour; Taha Merghoub; Jedd Wolchok; Alexandra Snyder; Jamie E Chaft; Mark G Kris; Charles M Rudin; Nicholas D Socci; Michael F Berger; Barry S Taylor; Ahmet Zehir; David B Solit; Maria E Arcila; Marc Ladanyi; Gregory J Riely; Nikolaus Schultz; Matthew D Hellmann
Journal:  J Clin Oncol       Date:  2018-01-16       Impact factor: 44.544

10.  A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma.

Authors:  Gregory D Jones; Whitney S Brandt; Ronglai Shen; Francisco Sanchez-Vega; Kay See Tan; Axel Martin; Jian Zhou; Michael Berger; David B Solit; Nikolaus Schultz; Hira Rizvi; Yuan Liu; Ariana Adamski; Jamie E Chaft; Gregory J Riely; Gaetano Rocco; Matthew J Bott; Daniela Molena; Marc Ladanyi; William D Travis; Natasha Rekhtman; Bernard J Park; Prasad S Adusumilli; David Lyden; Marcin Imielinski; Marty W Mayo; Bob T Li; David R Jones
Journal:  JAMA Surg       Date:  2021-02-10       Impact factor: 14.766

View more
  1 in total

1.  Prognostic and predictive value of radiomic signature in stage I lung adenocarcinomas following complete lobectomy.

Authors:  Wei Nie; Guangyu Tao; Zhenghai Lu; Jie Qian; Yaqiong Ge; Shuyuan Wang; Xueyan Zhang; Hua Zhong; Hong Yu
Journal:  J Transl Med       Date:  2022-07-28       Impact factor: 8.440

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.